PURPOSE OF REVIEW: None of the medications used in clinical practice to treat sarcoidosis have been approved by the regulatory authorities. Understanding how to use disease-modifying antisarcoid drugs, however, is essential for physicians treating patients with sarcoidosis. This review summarizes the recent studies of medications used for sarcoidosis with a focus on nonsteroidal therapies. Studies from 2006 to 2013 were considered for review to update clinicians on the most relevant literature published over the last few years. RECENT FINDINGS: Several recently published pieces of evidence have helped expand our ability to more appropriately sequence second-line and third-line therapies for sarcoidosis. For instance, methotrexate and azathioprine may be useful and well tolerated medications as second-line treatment. Mycophenolate mofetil might have a role in neurosarcoidosis. TNF-α blockers and other biologics seem to be well tolerated medications for the most severely affected patients. SUMMARY: Corticosteroids remain the first-line therapy for sarcoidosis as many patients never require treatment or only necessitate a short treatment duration. Second-line and third-line therapies described in this article should be used in patients with progressive or refractory disease or when life-threatening complications are evident at the time of presentation.
PURPOSE OF REVIEW: None of the medications used in clinical practice to treat sarcoidosis have been approved by the regulatory authorities. Understanding how to use disease-modifying antisarcoid drugs, however, is essential for physicians treating patients with sarcoidosis. This review summarizes the recent studies of medications used for sarcoidosis with a focus on nonsteroidal therapies. Studies from 2006 to 2013 were considered for review to update clinicians on the most relevant literature published over the last few years. RECENT FINDINGS: Several recently published pieces of evidence have helped expand our ability to more appropriately sequence second-line and third-line therapies for sarcoidosis. For instance, methotrexate and azathioprine may be useful and well tolerated medications as second-line treatment. Mycophenolate mofetil might have a role in neurosarcoidosis. TNF-α blockers and other biologics seem to be well tolerated medications for the most severely affected patients. SUMMARY: Corticosteroids remain the first-line therapy for sarcoidosis as many patients never require treatment or only necessitate a short treatment duration. Second-line and third-line therapies described in this article should be used in patients with progressive or refractory disease or when life-threatening complications are evident at the time of presentation.
Authors: G Androdias; D Maillet; R Marignier; L Pinède; C Confavreux; C Broussolle; S Vukusic; P Sève Journal: Neurology Date: 2011-03-29 Impact factor: 9.910
Authors: Carmen Bejerano; Ricardo Blanco; Carmen González-Vela; Ramón Agüero; José M Carril; Miguel A González-Gay Journal: Clin Exp Rheumatol Date: 2012-05-11 Impact factor: 4.473
Authors: Robert P Baughman; Marjolein Drent; Mani Kavuru; Marc A Judson; Ulrich Costabel; Roland du Bois; Carlo Albera; Martin Brutsche; Gerald Davis; James F Donohue; Joachim Müller-Quernheim; Rozsa Schlenker-Herceg; Susan Flavin; Kim Hung Lo; Barry Oemar; Elliot S Barnathan Journal: Am J Respir Crit Care Med Date: 2006-07-13 Impact factor: 21.405
Authors: R J Erckens; R L M Mostard; P A H M Wijnen; J S Schouten; M Drent Journal: Graefes Arch Clin Exp Ophthalmol Date: 2011-11-27 Impact factor: 3.117
Authors: Nadera J Sweiss; Elyse E Lower; Mehdi Mirsaeidi; Steven Dudek; Joe G N Garcia; David Perkins; Patricia W Finn; Robert P Baughman Journal: Eur Respir J Date: 2014-01-31 Impact factor: 16.671
Authors: Gillian Murtagh; Luke J Laffin; Kershaw V Patel; Amit V Patel; Catherine A Bonham; Zoe Yu; Karima Addetia; Nadia El-Hangouche; Francesco Maffesanti; Victor Mor-Avi; D Kyle Hogarth; Nadera J Sweiss; John F Beshai; Roberto M Lang; Amit R Patel Journal: Echocardiography Date: 2016-09 Impact factor: 1.724